Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anebulo Pharmaceuticals Inc (NQ: ANEB ) 2.050 +0.090 (+4.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Anebulo Pharmaceuticals Inc < Previous 1 2 3 4 Next > Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates September 25, 2024 From Anebulo Pharmaceuticals, Inc. Via Business Wire Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects July 22, 2024 From Anebulo Pharmaceuticals, Inc. Via Business Wire Lifecore Biomedical Announces Cooperation Agreement with 22NW July 01, 2024 Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board From Lifecore Biomedical, Inc. Via GlobeNewswire Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says September 18, 2023 H.C. Via Benzinga Anebulo Pharmaceuticals: Q3 Earnings Insights May 11, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session May 31, 2024 Via Benzinga ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024 May 15, 2024 ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024. Via InvestorPlace Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates May 15, 2024 From Anebulo Pharmaceuticals, Inc. Via Business Wire Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug February 14, 2024 Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The... Via Benzinga Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates February 13, 2024 From Anebulo Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session December 21, 2023 Via Benzinga Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates November 14, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session October 17, 2023 Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session October 17, 2023 Via Benzinga Anebulo Pharmaceuticals Announces New CEO October 06, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors October 06, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates September 20, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences August 30, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023 September 18, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session August 22, 2023 Via Benzinga Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication August 21, 2023 Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration following a type B meeting in July. Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session August 21, 2023 Via Benzinga Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension August 21, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication March 29, 2023 Anebulo Pharmaceuticals, Inc. Via Benzinga Latest Executive Changes In Marijuana Industry, New Appointments & Resignations March 13, 2023 As the Benzinga Cannabis Capital Conference returns to Miami (April 11-12), gathering top CEOs, investors and leaders in the mari Via Benzinga Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 07, 2023 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... Via Benzinga Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates February 10, 2023 From Anebulo Pharmaceuticals, Inc. Via Business Wire Acute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat Symptoms January 09, 2023 Anebulo Pharmaceuticals, Inc. Via Benzinga Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 30, 2023 Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 136% to $2.06 after Ascendant Capital initiated coverage on the stock with a Buy rating and a $3.30 price target. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.